Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions

NCT: NCT06994416 · ACTIVE_NOT_RECRUITING

NCT IDNCT06994416
StatusACTIVE_NOT_RECRUITING
Start Date2025-06-01
Completion2026-12-31
SponsorThe Fourth Affiliated Hospital of China Medical University (OTHER)
First posted
Last updated

Brief Summary

This retrospective cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding quantum dot chiral nanofluorescent coating, in contrast to traditional localization techniques for breast duct lesions. The primary goal is to evaluate the clinical effectiveness of this innovative fluorescent localization needle in facilitating accurate pathological diagnoses of micro lesions situated within breast ducts.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑